Quick Answer
Denali Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $205.33 million for the year ending 2025.
- Denali Therapeutics Inc. showed an increase of +17.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $36.75 million | Q2 2017: $41.31 million | Q3 2017: $36.27 million | Q1 2018: $44.00 million | Q2 2018: $33.09 million | Q3 2018: $43.65 million | Q4 2018: $77.12 million | Q1 2019: $39.66 million | Q2 2019: $62.94 million | Q3 2019: $82.67 million | Q1 2020: $207.54 million | Q2 2020: $137.18 million | Q3 2020: $351.05 million | Q1 2021: $435.32 million | Q2 2021: $485.68 million | Q3 2021: $394.55 million | Q1 2022: $104.95 million | Q2 2022: $155.09 million | Q3 2022: $118.62 million | Q1 2023: $68.13 million | Q2 2023: $131.97 million | Q3 2023: $148.01 million | Q1 2024: $60.57 million | Q2 2024: $74.68 million | Q3 2024: $90.64 million | Q1 2025: $56.95 million | Q2 2025: $141.21 million | Q3 2025: $90.96 million.
- Over the full 10 years of available data (2016 to 2025), Denali Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 415.2%.
- Historical annual values: Fiscal year 2025: $205.33 million | Fiscal year 2024: $174.96 million | Fiscal year 2023: $127.11 million | Fiscal year 2022: $218.04 million | Fiscal year 2021: $293.48 million | Fiscal year 2020: $507.14 million | Fiscal year 2019: $79.45 million | Fiscal year 2018: $77.12 million | Fiscal year 2017: $218.38 million | Fiscal year 2016: $39.85 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: